

Immunological characterization of abnormal prion protein from atypical scrapie cases in sheep using a panel of monoclonal antibodies

Anja Gretzschel,¹ Anne Buschmann,¹ Jan Langeveld²
and Martin H. Groschup¹

Correspondence
Martin H. Groschup
martin.groschup@fli.bund.de

¹Institute for Novel and Emerging Infectious Diseases at the Friedrich-Loeffler-Institut, Boddenblick 5a, 17493 Greifswald-Insel Riems, Germany

²Central Institute for Animal Disease Control, PO Box 2004, 8203 AA Lelystad, The Netherlands

After the implementation of an active surveillance programme for scrapie in sheep in the EU, the number of diagnosed classical scrapie cases rose sharply and a novel kind of so-called atypical scrapie case was discovered. These atypical scrapie cases display unusual features concerning the distribution of the abnormal prion protein (PrP^{Sc}) in the brain, a distinct electrophoretic profile of PrP^{Sc} and an inconsistent reaction pattern in the currently used rapid tests. In this report, PrP^{Sc} of two German atypical sheep scrapie cases was characterized by epitope mapping using a panel of 18 monoclonal antibodies that were directed against epitopes located throughout the prion protein. This analysis suggests that PrP^{Sc} derived from atypical scrapie cases and treated with proteinase K is largely composed of an 11 kDa fragment (previously referred to as the 12 kDa band) and of polymeric fragments thereof. The 11 kDa band corresponds to a prion protein fragment spanning approximately aa 90–153 and may therefore represent a novel PrP^{Sc} type.

Received 6 January 2006

Accepted 31 July 2006

INTRODUCTION

Transmissible spongiform encephalopathies (TSEs) are a group of fatal, neurodegenerative diseases that include scrapie in sheep and goats, as well as bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt–Jakob disease in humans. TSEs are associated with the accumulation of an abnormal isoform (PrP^{Sc}) of the host-encoded prion protein, PrP^C. In contrast to PrP^C, PrP^{Sc} shows a partial resistance to digestion with proteinase K (PK).

The implementation of an obligatory active surveillance programme for scrapie in 2002 resulted in an increase of diagnosed classical scrapie cases in all EU member states. Moreover, atypical scrapie cases were newly discovered that were similar, if not identical, to the so-called Nor98 cases that were found previously in Norway (Benestad *et al.*, 2003). Atypical scrapie cases have been reported in Germany, France, Portugal, Ireland, Sweden, Belgium and elsewhere (Buschmann *et al.*, 2004a; Orge *et al.*, 2004; Onnasch *et al.*, 2004; Gavier-Widen *et al.*, 2004; De Bosschere *et al.*, 2004).

In Germany, approximately 45% of all currently diagnosed scrapie cases and 84% of the affected flocks represent atypical scrapie. The atypical phenotype is characterized by the absence of or a faint and mostly granular deposition of PrP^{Sc} at the level of the obex. On the other hand, in the

majority of cases, massive accumulations of PrP^{Sc} are detectable in the cerebellum and cerebrum. The PrP^{Sc} electrophoretic profile by Western blot is different from that of classical scrapie cases and includes an additional fragment with a molecular mass of approximately 12 kDa (Benestad *et al.*, 2003; Buschmann *et al.*, 2004a).

The abnormal PrP^{Sc} derived from atypical scrapie cases displays a lower resistance to PK than does PrP^{Sc} from classical scrapie. Furthermore, these scrapie cases are diagnosed only by one (Bio-Rad TeSeE, formerly Bio-Rad Platelia) of the four currently used rapid tests (Buschmann *et al.*, 2004a). Although atypical scrapie cases are frequently found only in single animals of an affected flock, atypical scrapie cases are indeed infectious when inoculated into transgenic mice (Le Dur *et al.*, 2005; G. Lühken, A. Buschmann, H. Brandt, M. Eiden, M. H. Groschup & G. Erhardt, unpublished data). Notably, such atypical scrapie cases were often found in sheep carrying PrP genotypes that were believed to convey scrapie resistance (Buschmann *et al.*, 2004b). It has been reported recently that polymorphisms at codons 141 and 154 in the ovine prion protein gene may be correlated with atypical scrapie cases (Moum *et al.*, 2005).

Here, we report differences in the immunoreactivity of PrP^{Sc} derived from atypical scrapie, from BSE and from classical scrapie after PK digestion. These differences were found

when a panel of monoclonal antibodies (mAbs) directed against a broad range of prion protein epitopes were used for PrP^{Sc} detection by Western blot.

METHODS

Animals and diagnostic confirmation. Two German atypical scrapie cases, S39/02 (genotype AHQ/ARR) and S40/04 (genotype AHQ/ARQ), were used for epitope mapping. One German classical scrapie case, S33/02 (genotype ARQ/ARQ), and a German BSE isolate, R128/04, served as controls. PrP^C of an undigested brain homogenate from a scrapie-negative sheep served as internal control for antibody binding on each Western blot. All described German TSE cases were confirmed by either scrapie-associated fibril (SAF) immunoblotting or immunohistochemistry, or by both methods according to the OIE manual (Anonymous, 2004; Gretzschel *et al.*, 2005).

Tissue treatment, SDS-PAGE and Western blotting. From all sheep or cattle samples, 10% (w/v) brain homogenates were prepared in 0.42 µM sucrose solution containing 0.5% deoxycholic acid sodium salt and 0.5% (w/v) Nonidet P40 by using a Ribolyser (Hybaid). Precipitation with phosphotungstic acid (PTA) was carried out according to the protocol established by Wadsworth *et al.* (2001) with some modifications (Gretzschel *et al.*, 2005). After PTA precipitation, samples were loaded on 16% Tris/polyacrylamide gels. Electrophoresis was carried out by using the Bio-Rad Mini Protean II system with a running buffer containing 25 mM Tris, 190 mM glycine and 3 mM SDS. If not mentioned otherwise, sample preparation, SDS-PAGE and Western blotting were carried out as described previously (Gretzschel *et al.*, 2005) using a panel of 18 mAbs (Table 1). All chemicals were derived from Sigma unless otherwise noted. The molecular mass markers Precision Plus Protein Standard Dual Colour and Precision Plus Protein Standard Unstained (both from Bio-Rad) were used, with fragment sizes of 10, 15, 20, 25, 37, 50, 75, 100, 150 and 250 kDa. Whilst the dual-colour standard is mostly recommended for molecular mass determination on gels and for the monitoring of transmission efficiency, the unstained marker is recommended for molecular mass determination on gels and Western blots.

PrP-specific antibodies. The following mAbs were used (Table 1): L42 and P4 (R-Biopharm), FH11 and BG4 (TSE Resource Centre, Compton, UK), F89/160.1.5 and F99/97.6.1 (VMRD Inc.), ICSM18 and ICSM35 (D-Gen), 6H4 (Prionics AG), 12B2, 9A2, 94B4, SAF32, SAF34, 8G8 and 12F10 [J. Grassi, Commissariat à l'Énergie Atomique (CEA), Gif-sur-Yvette, France], R145 [Community Reference Laboratory, Veterinary Laboratories Agency (VLA), Weybridge, UK] and 3B5 (W. Bodemer, German Centre for Primates, Göttingen, Germany).

Seventeen of these antibodies were mouse mAbs, which were subsequently incubated with a secondary antibody (alkaline phosphatase-conjugated anti-mouse immunoglobulin; Dianova) at 0.15 µg ml⁻¹. Only mAb R145 was a rat mAb, which was incubated with an alkaline phosphatase-conjugated anti-rat immunoglobulin (Dianova) at 0.15 µg ml⁻¹. All antibodies were tested with undigested, as well as with PK-digested, brain homogenates. Before precipitation, PK digestion was performed for 1 h at 55 °C, using a final concentration of 50 µg ml⁻¹.

Pepscan analysis. To detect the linear epitope specificities of mAbs L42, 12B2, 9A2, 6H4, 8G8, 94B4, 12F10, F89/160.1.5, F99/97.6.1, BG4 and FH11, Pepscan analyses of antibodies were performed in an ELISA-like procedure on solid-phase synthetic peptides bound to plastic surfaces, as described by Geysen *et al.* (1984) and Thuring *et al.* (2004). Complete sets of overlapping 15mer peptides

were synthesized based on the amino acid sequence of the ovine PrP (GenBank accession no. AJ000739). A site was considered positive (i.e. antigenic) when the A_{405} values of two or more consecutive peptides were at least three times the background. The background was calculated as the mean A_{405} value measured for 20 consecutive peptides with low levels of reaction, where the standard deviation (SD) was 20% of the mean A_{405} value. A linear epitope (or epitope core) was defined as the sequence of amino acids common to all antigenic peptides in a site.

Genotyping. PrP genotypes of the German TSE sheep were determined as described previously (Lühken *et al.*, 2004).

RESULTS

The immunoblot patterns of PrP^{Sc} derived from classical and atypical scrapie cases were similar to those reported in the literature, i.e. the different glycoforms of classical PrP^{Sc} had molecular masses of approximately 36, 33 and 29 kDa that shifted down to 28, 21 and 17.5 kDa following PK treatment. In contrast to this, PrP^{Sc} derived from atypical scrapie cases displayed one major, distinct band of a low molecular mass and three to five additional bands ranging from 15 to 30 kDa in size. Repeated measurements of the size of this low-molecular-mass PrP^{Sc} band, previously described as the 12 kDa band in the literature (Benestad *et al.*, 2003), consistently gave it a lower molecular size in our hands. The size of this band was therefore determined by using a molecular size marker with 5 kDa increments from 10 to 25 kDa (Fig. 1). This measurement reproducibly gave a molecular size of about 11 kDa, so this band is referred to as the '11 kDa fragment' in this report.

Eighteen antibodies were used for immunochemical characterization of PrP^{Sc} of classical and atypical scrapie cases before and after digestion with PK. These antibodies were divided into five groups according to the PrP epitopes that they detect (Table 1).

Two mAbs, FH11 (Fig. 2a, b; Table 2) and BG4, which recognize epitopes at the N terminus of the prion protein (aa 54–58), detected the undigested PrP of atypical and classical scrapie cases, as well as that from the BSE isolate. However, the 11 kDa fragment of the atypical scrapie cases was detected only faintly, if at all. After PK digestion, these antibodies failed to recognize all TSE isolates.

mAb 3B5 (group 2; Fig. 2c, d; Table 2) recognizes aa 51–90 of the prion protein. Prior to PK digestion, mAb 3B5 detected classical scrapie and the upper fragments of atypical scrapie and also the BSE isolate, but again, the 11 kDa fragment of the atypical scrapie cases was detected very weakly or not at all. After PK digestion, this antibody recognized only classical scrapie, but failed to recognize atypical scrapie or the BSE isolate.

Five mAbs of group 3 (12B2, P4, 8G8, SAF32, SAF34), which were raised against an epitope close to the PK-cleavage site, epitope-mapped to the region from aa 59 to 107 of the prion protein. Without PK digestion, they detected classical

Table 1. Characteristics of mAbs used for Western blotting

Rec, recombinant; ov, ovine; hu, human; bo, bovine; ha, hamster; SAF, scrapie-associated fibrils resistant to PK.

Antibody	Linear epitope on ov PrP*	Immunogen	Species tested and recognized†	Antibody concentration		Reference(s)
				Stock ($\mu\text{g Ig ml}^{-1}$)	Working dilution for sheep	
FH11	54–58	rec ov PrP	Sheep, cattle, hamster, human	1000	1:1000	Jeffrey <i>et al.</i> (2001); present paper
BG4	54–57	rec bo PrP	Sheep, cattle, hamster, human	1000	1:1000	Jeffrey <i>et al.</i> (2001); Martin <i>et al.</i> (2005); present paper
3B5	51–90	rec hu PrP	Sheep, cattle, mouse	–	1:20	Bodemer (1999)
SAF32	59–89	ha SAF	Sheep, cattle, mouse, hamster, human	–	1:1000	Féraudet <i>et al.</i> (2005)
SAF34	59–89	ha SAF	Sheep, cattle, mouse, hamster, human	–	1:1000	Féraudet <i>et al.</i> (2005); Moudjou <i>et al.</i> (2001)
12B2	93–97	bo PrP peptide	Sheep, cattle, mouse, human, deer	1700	1:666	Jeffrey <i>et al.</i> (2006); Yull <i>et al.</i> (2006)
P4	93–99	ov PrP peptide	Cattle, sheep	1000	1:2500	Hardt <i>et al.</i> (2000); Harmeyer <i>et al.</i> (1998); Thuring <i>et al.</i> (2004)
8G8	100–107	rec hu PrP	Sheep, cattle, mouse, hamster, human	–	1:1000	Féraudet <i>et al.</i> (2005); Krasemann <i>et al.</i> (1996, 1999); present paper
ICSM35	93–102	hu PrP	Sheep, cattle, mouse, hamster, human	3000	1:2857	Beringue <i>et al.</i> (2003); White <i>et al.</i> (2003)
9A2	102–104	bo PrP peptide	Sheep, cattle, mouse, human, deer	2000	1:2000	Yull <i>et al.</i> (2006)
F89	140–147	bo PrP peptide	Sheep, cattle, deer, human	1000	1:333	O'Rourke <i>et al.</i> (1998, 2000); present paper
L42	148–153	ov PrP peptide	Sheep, cattle, mink, human	1000	1:2500	Hardt <i>et al.</i> (2000); Harmeyer <i>et al.</i> (1998); present paper
12F10	146–155	rec hu PrP	Sheep, cattle, human	–	1:1000	Krasemann <i>et al.</i> (1996, 1999); Féraudet <i>et al.</i> (2005); present paper
ICSM18	146–156	hu PrP	Sheep, cattle, mouse, hamster, human	3600	1:3333	Beringue <i>et al.</i> (2003); White <i>et al.</i> (2003)
6H4	148–157	rec hu PrP	Sheep, cattle, mouse, hamster, mink, human	–	1:10 000	Korth <i>et al.</i> (1997); present paper
94B4	190–197	rec bo and hu PrP	Cattle, sheep	650	1:1666	Thuring <i>et al.</i> (2004); present paper
R145	221–234	bo PrP peptide	Cattle, sheep	1000	1:250	Jeffrey <i>et al.</i> (2001, 2003)
F99	221–224	ov PrP peptide	Sheep, cattle, deer	1000	1:333	O'Rourke <i>et al.</i> (2000); Spraker <i>et al.</i> (2002); present paper

*This represents at least part of the epitope.

†This column is not exhaustive.

scrapie, as well as atypical scrapie with the 11 kDa fragment and also the BSE isolate. After PK digestion, these antibodies failed to recognize the BSE isolate, but clearly detected the classical and the atypical scrapie cases, including the 11 kDa fragment. Examples of the results obtained with mAb 12B2 are shown in Fig. 2(e, f) and Table 2.

The region from aa 93 to 163 was covered by five antibodies of group 4 (L42, ICSM35, 9A2, F89/160.1.5). They detected PrP^{Sc} derived from classical scrapie, atypical scrapie including the 11 kDa fragment and the BSE isolate, both before and after PK digestion. Results obtained from L42 are shown (Fig. 2g, h; Table 2).




Fig. 1. Determination of the molecular sizes of PTA-precipitated and PK-treated PrP^{Sc} derived from atypical and classical scrapie cases. PTA-precipitated and PK-treated PrP^{Sc} derived from atypical scrapie cases [lanes 3 (S30/05) and 6 (S40/04)], as well as from a classical scrapie case (lane 5), was immunoblotted and visualized by using mAb L42 as detection antibody. Molecular sizes were determined by using two molecular mass markers: lanes 1 and 4, Precision Plus Protein Standard Dual Colour; lane 2, Precision Plus Protein Standard Unstained (both from Bio-Rad). Fragment sizes of 10, 15, 20, 25 and 50 kDa are displayed.

Six mAbs of group 5, which epitope-mapped between aa 146 and 224 of the prion protein (ICSM18, 94B4, 6H4,12F10, R145 and F99/97.6.1), recognized PrP^{Sc} of classical scrapie, of the BSE isolate and the upper fragments of atypical scrapie before PK digestion. However, after PK digestion, the atypical scrapie cases were not detected by these antibodies, as shown for antibody ICSM18 (Fig. 2i, j; Table 2).

DISCUSSION

In contrast to PrP^C, PrP^{Sc} derived from classical as well as from atypical scrapie cases exhibits a remarkable partial resistance to digestion with PK. This is due to the increased β -sheet content in the PrP core following conversion from the normal α -helical form. As a consequence, only the unstructured, flexible N terminus can be degraded proteolytically. According to our data, PrP^{Sc} derived from atypical scrapie cases differs substantially from that of classical scrapie cases. The N-terminal PK-cleavage site seems to be a




Fig. 2. Western blot analysis of PTA-precipitated PrP^{Sc} without (a, c, e, g, i) or with (b, d, f, h, j) PK digestion. PrP^{Sc} was derived from classical scrapie case S33/02 (lanes 1 and 6), BSE isolate R128/04 (lanes 3 and 7) and two atypical scrapie cases, S39/02 (lane 8) and S40/04 (lanes 2 and 9). Lanes 4 and 5 display non-PK-digested PrP^C of a scrapie-negative sheep. M represents a molecular mass marker with fragments of 23.0, 21.5, 20.3, 19.2, 18.0, 17.1 and 16.2 kDa. Detection was carried out with antibodies detecting different regions of the prion protein: mAb FH11, group 1 (Fig. 1a, b); mAb 3B5, group 2 (Fig. 1c, d); mAb 12B2, group 3 (Fig. 1e, f); mAb L42, group 4 (Fig. 1g, h); mAb ICSM18, group 5 (Fig. 1i, j).

Table 2. Classification of antibodies according to the binding affinity towards PrP^{Sc} derived from atypical scrapie cases in Western blot

–, No signal in Western blot; ±, weak signal in Western blot; +, slight signal in Western blot; ++, moderate signal in Western blot; + + +, strong signal in Western blot; ND, not done.

Group	mAb	Linear epitope on PrP	–PK					+PK					
			Classical scrapie S33/02	Atypical scrapie S40/04		BSE R128/04	Scrapie-negative sheep	Classical scrapie S33/02	Atypical scrapie S39/02		Atypical scrapie S40/04		BSE R128/04
				Upper fragments	11 kDa fragment				Upper fragments	11 kDa fragment	Upper fragments	11 kDa fragment	
1	FH11	54–57	++	++	–	++	++	–	–	–	–	–	
	BG4	54–58	++	+++	–	++	++	–	–	–	–	–	
2	3B5	51–90	++	+++	+	+++	++	++	–	–	–	–	
3	SAF32	59–89	++	+++	+	++	++	++	+	±	+	±	
	SAF34	59–89	++	+++	+	++	++	++	+	±	+	±	
4	12B2	93–97	+++	+++	+	++	++	+++	++	+	+++	+	
	P4	93–99	++	+	+	±	++	+++	+++	+	+++	+	
	8G8	100–107	+++	+++	+	±	++	+++	+	+	++	+	
	ICSM35	93–102	+++	+++	+	++	++	+++	+	+	++	+	
5	9A2	102–104	++	+++	+	++	+	+++	+++	+	+++	+	
	F89	140–147	+	++	+	+	+	+	+	+	+	+	
	L42	148–153	++	+++	+	++	++	+++	+++	+	+++	+	
5	12F10	146–155	+	+	–	+++	+	++	ND	ND	–	–	
	ICSM18	146–156	+++	+++	–	+++	+++	+++	–	–	–	–	
	6H4	148–157	++	++	–	+++	+	+++	ND	ND	–	–	
	94B4	190–197	ND	ND	ND	ND	ND	++	–	–	–	–	
	R145	221–234	++	++	–	++	++	++	ND	ND	–	–	
	F99	221–224	+	+	±	±	+	++	–	–	–	–	

few amino acids further towards the C terminus of the protein, still being closer to that determined for classical scrapie than to that determined for BSE. Furthermore, our results indicate clearly that the 11 kDa band (which was formerly designated the 12 kDa fragment) observed in PK-treated atypical scrapie PrP^{Sc} constitutes only a minor fragment of the prion protein. Incidentally, to form this fragment, PrP^{Sc} must be trimmed proteolytically from the N terminus as well as the C terminus, so that only a core peptide spanning aa 90–153 (an estimate based on the mAb-binding sites) is retained. Moreover, based on the distinct mAb-binding patterns and respective molecular sizes, we propose that the upper bands in immunoblotted PrP^{Sc} derived from atypical scrapie cases may represent multimers of the 11 kDa band or of fragments thereof.

These results were obtained by immunochemical characterization of PrP^{Sc} of atypical scrapie cases using 18 different mAbs binding to all parts of the ovine prion protein. According to their reaction patterns (particularly on PrP^{Sc} of atypical cases), these antibodies can be clustered generally into five groups. Minor deviations in particular mAbs from these reaction patterns are perhaps due to overlapping or incomplete epitopes that are present or lacking on PrP^{Sc}.

Antibodies belonging to group 1 bind to the N terminus of the prion protein (group 1); these detect PrP^{Sc} before PK

digestion, but fail to detect the cleaved N terminus after PK digestion. However, the 11 kDa fragment of atypical scrapie cases was not detected by these antibodies even before PK digestion. We therefore conclude that this flexible, N-terminal epitope of the prion protein is not present in the 11 kDa fragment of atypical scrapie cases (Fig. 3).

The exact N-terminal PK-cleavage site of PrP^{Sc} depends on the particular prion strain and on the applied reaction conditions. For discrimination between BSE and scrapie, the difference in the strain-specific N-terminal PK-cleavage sites, which vary from aa 81 to 89 for scrapie and aa 96 to 97 for BSE (Hayashi *et al.*, 2005), is targeted. Thus, mAbs raised against an epitope between positions 75 and 89 of the prion protein detect scrapie-derived PrP^{Sc} very well, but fail to recognize bovine or ovine BSE.

mAb 3B5, representing group 2 of the applied antibodies, binds close to the PK-cleavage site and can therefore be used for the discrimination between BSE and scrapie (Groschup *et al.*, 2000), like antibodies from group 3 (Baron & Biacabe, 2001; Stack *et al.*, 2002). However, although mAb 3B5 has a reaction pattern similar to that of these antibodies with BSE and classical scrapie PrP^{Sc}, it fails to detect PrP^{Sc} derived from atypical scrapie cases after strong PK digestion. Furthermore, mAb 3B5 detects the 11 kDa fragment of atypical scrapie cases before PK digestion either very weakly




Fig. 3. Antibody epitopes of PrP^{Sc} derived from classical scrapie, atypical scrapie and BSE before and after PK digestion. PK-cleavage sites of PrP^{Sc} from BSE and classical scrapie are indicated (Hayashi *et al.*, 2005). The areas around the different PK-cleavage sites are depicted as being disproportionately large to illustrate better the proposed differences.

or not at all, indicating that this epitope is poorly preserved in this fragment. From our results, we therefore postulate that the N terminus of PrP^{Sc} derived from atypical scrapie cases seems to be cleaved off some amino acids further into the protein than PrP^{Sc} of the classical scrapie cases, but not as far as that of PrP^{Sc} from BSE-infected brain. It needs to be pointed out that the PK digestion in our study was comparably harsh, which may explain the discordant results obtained regarding the binding of antibodies raised against the region of the PK-cleavage site of PrP^{Sc} compared with previous publications (Benestad *et al.*, 2003; Le Dur *et al.*, 2005; Onnasch *et al.*, 2004).

The stringency of the PK treatment has a major impact on the preservation of the epitope accessibility or presentation for mAbs 3B5, SAF32 and SAF34. This cleavage is not a mechanistic, but rather a kinetic, process and the epitopes for these mAbs are destroyed to a greater or lesser degree depending on the proteolytic conditions used. This may explain why mAbs SAF32 and SAF34 react slightly differently from mAb 3B5 and are able to detect (albeit only weakly) atypical scrapie-derived PrP^{Sc}. Although all three mAbs react strongly to the same linear epitope as determined by peptide mapping (Féraudet *et al.*, 2005), an additional reactivity to a non-linear site at the N terminus of PK-treated atypical PrP^{Sc} derived from atypical scrapie cases cannot be ruled out.

Antibodies of group 3 also bind to epitopes close to the PK-cleavage site, but these epitopes seem to be located a few amino acids further C-terminally into the protein, as they detect PrP^{Sc} derived from the classical as well as atypical scrapie cases, but fail to detect BSE-derived PrP^{Sc} after PK

digestion. Therefore, the PK-cleavage site of atypical scrapie cases seems to be equidistant from or even closer to the PK-cleavage site of scrapie than to the PK-cleavage site of BSE. The 11 kDa fragment of atypical scrapie cases is detected easily by the antibodies of group 3 before and after PK digestion, although mAbs SAF 32 and SAF34 seem to bind somewhat more weakly than mAbs 12B2, P4 and 8G8. Thus, this epitope is present in atypical scrapie cases before and after PK digestion (Fig. 3).

Antibodies of group 4 detect classical scrapie, atypical scrapie including the 11 kDa fragment and the BSE isolate equally well before and after PK digestion. Therefore, this region represents the PK-resistant core not only of PrP^{Sc} derived from classical scrapie and BSE, but also of PrP^{Sc} derived from atypical scrapie cases (Fig. 3).

Antibodies of group 5 fail to detect the 11 kDa fragment of atypical scrapie cases even before PK digestion and do not recognize the upper fragments or the 11 kDa fragment of atypical scrapie cases after PK digestion. Therefore, this 11 kDa band seems not to extend beyond approximately aa 153 towards the C terminus of the protein. The proteolysis of the C terminus also appears to take place *in vivo*, as this band is also not detectable in non-PK-treated preparations. However, the origin of the upper bands of undigested PrP^{Sc} derived from atypical scrapie cases remains unclear, because their signals may be superimposed by the signals of non- or only partially cleaved PrP^C or PrP^{Sc} moieties.

Our findings are reminiscent of the major PrP^{Sc} peptide fragment found in amyloid fibrils extracted from familial Gerstmann–Sträussler–Scheinker (GSS) syndrome victims (Salmona *et al.*, 2003; Tagliavini *et al.*, 2001). This major amyloid component spans the residues of approximately aa 82–146 of human PrP and has an approximate size of 7 kDa. Synthetic peptides of this amino acid sequence easily form amyloidotic aggregates that are partially resistant to protease digestion and assemble to form fibrils with a parallel cross- β structure. It is conceivable that the 11 kDa fragment observed in atypical scrapie originates – similarly to the GSS fragment – from full-length PrP^{Sc}, which is deposited in the extracellular compartment and partially degraded by proteases, and then further digested by tissue endopeptidases.

Taken together, we propose that PTA-precipitated and PK-treated PrP^{Sc} derived from atypical scrapie is largely composed of a novel and unique fraction of the prion protein. The infectious nature of this fraction and its potential molecular and cellular pathomechanism remain to be established.

ACKNOWLEDGEMENTS

The authors wish to thank Jacques Grassi (CEA, Gif-sur-Yvette, France) for so generously supplying us with mAbs. Moreover, we acknowledge Marion Simmons (Community Reference Laboratory, VLA, Weybridge, UK) for kindly providing mAb R145, and Walter

Bodemer (German Centre for Primates, Göttingen, Germany) for supplying us with mAb 3B5. Furthermore, we thank Gesine Kreplin for her excellent technical support.

REFERENCES

- Anonymous (2004).** Bovine spongiform encephalopathy. In *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (Mammals, Birds and Bees)*, vol. 2, chapter 2.3.13, pp. 642–653. Paris: World Organisation for Animal Health (OIE).
- Baron, T. G. M. & Biacabe, A.-G. (2001).** Molecular analysis of the abnormal prion protein during coinfection of mice by bovine spongiform encephalopathy and a scrapie agent. *J Virol* **75**, 107–114.
- Benestad, S. L., Sarradin, P., Thu, B., Schonheit, J., Tranulis, M. A. & Bratberg, B. (2003).** Cases of scrapie with unusual features in Norway and designation of a new type, Nor98. *Vet Rec* **153**, 202–208.
- Beringue, V., Mallinson, G., Kaiser, M., Tayebi, M., Sattar, Z., Jackson, G., Anstee, D., Collinge, J. & Hawke, S. (2003).** Regional heterogeneity of cellular prion protein isoforms in the mouse brain. *Brain* **126**, 2065–2073.
- Bodemer, W. (1999).** The use of monoclonal antibodies in human prion disease. *Naturwissenschaften* **86**, 212–220.
- Buschmann, A., Biacabe, A.-G., Ziegler, U., Bencsik, A., Madec, J.-Y., Erhardt, G., Lühken, G., Baron, T. & Groschup, M. H. (2004a).** Atypical scrapie cases in Germany and France are identified by discrepant reaction patterns in BSE rapid tests. *J Virol Methods* **117**, 27–36.
- Buschmann, A., Lühken, G., Schultz, J., Erhardt, G. & Groschup, M. H. (2004b).** Neuronal accumulation of abnormal prion protein in sheep carrying a scrapie-resistant genotype (PrP^{ARR/ARR}). *J Gen Virol* **85**, 2727–2733.
- De Bosschere, H., Roels, S., Benestad, S. L. & Vanopdenbosch, E. (2004).** Scrapie case similar to Nor98 diagnosed in Belgium via active surveillance. *Vet Rec* **155**, 707–708.
- Féraudet, C., Morel, N., Simon, S., Volland, H., Frobert, Y., Créminon, C., Vilette, D., Lehmann, S. & Grassi, J. (2005).** Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrP^{Sc} replication in infected cells. *J Biol Chem* **280**, 11247–11258.
- Gavier-Widen, D., Nöremark, M., Benestad, S., Simmons, M., Renström, L., Bratberg, B., Elvander, M. & af Segerstad, C. H. (2004).** Recognition of the Nor98 variant of scrapie in the Swedish sheep population. *J Vet Diagn Invest* **16**, 562–567.
- Geysen, H. M., Meloan, R. H. & Barteling, S. J. (1984).** Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. *Proc Natl Acad Sci U S A* **81**, 3998–4002.
- Gretzschel, A., Buschmann, A., Eiden, M., Ziegler, U., Lühken, G., Erhardt, G. & Groschup, M. H. (2005).** Strain typing of German transmissible spongiform encephalopathies field cases in small ruminants by biochemical methods. *J Vet Med B Infect Dis Vet Public Health* **52**, 55–63.
- Groschup, M. H., Kuczius, T., Junghans, F., Sweeney, T., Bodemer, W. & Buschmann, A. (2000).** Characterization of BSE and scrapie strains/isolates. *Arch Virol* **16**, 217–226.
- Hardt, M., Baron, T. & Groschup, M. H. (2000).** A comparative study of immunohistochemical methods for detecting abnormal prion protein with monoclonal and polyclonal antibodies. *J Comp Pathol* **122**, 43–53.
- Harmeyer, S., Pfaff, E. & Groschup, M. H. (1998).** Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants. *J Gen Virol* **79**, 937–945.
- Hayashi, H. K., Yokoyama, T., Takata, M., Iwamaru, Y., Imamura, M., Ushiki, Y. K. & Shinagawa, M. (2005).** The N-terminal cleavage site of PrP^{Sc} from BSE differs from that of PrP^{Sc} from scrapie. *Biochem Biophys Res Commun* **328**, 1024–1027.
- Jeffrey, M., Martin, S., González, L., Ryder, S. J., Bellworthy, S. J. & Jackman, R. (2001).** Differential diagnosis of infections with the bovine spongiform encephalopathy (BSE) and scrapie agents in sheep. *J Comp Pathol* **125**, 271–284.
- Jeffrey, M., Martin, S. & González, L. (2003).** Cell-associated variants of disease-specific prion protein immunolabelling are found in different sources of sheep transmissible spongiform encephalopathy. *J Gen Virol* **84**, 1033–1046.
- Jeffrey, M., Martin, S., González, L., Foster, J., Langeveld, J. P. M., van Zijderveld, F. G., Grassi, J. & Hunter, N. (2006).** Immunohistochemical features of PrP^d accumulation in natural and experimental goat transmissible spongiform encephalopathies. *J Comp Pathol* **134**, 171–181.
- Korth, C., Stierli, B., Streit, P. & 14 other authors (1997).** Prion (PrP^{Sc})-specific epitope defined by a monoclonal antibody. *Nature* **390**, 74–77.
- Krasemann, S., Groschup, M. H., Harmeyer, S., Hunsmann, G. & Bodemer, W. (1996).** Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. *Mol Med* **2**, 725–734.
- Krasemann, S., Jürgens, T. & Bodemer, W. (1999).** Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. *J Biotechnol* **73**, 119–129.
- Le Dur, A., Béringue, V., Andréoletti, O. & 8 other authors (2005).** A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes. *Proc Natl Acad Sci U S A* **102**, 16031–16036.
- Lühken, G., Buschmann, A., Groschup, M. H. & Erhardt, G. (2004).** Prion protein allele A₁₃₆ H₁₅₄ Q₁₇₁ is associated with high susceptibility to scrapie in purebred and crossbred German Merinoland sheep. *Arch Virol* **149**, 1571–1580.
- Martin, S., González, L., Chong, A., Houston, F. E., Hunter, N. & Jeffrey, M. (2005).** Immunohistochemical characteristics of disease-associated PrP are not altered by host genotype or route of inoculation following infection of sheep with bovine spongiform encephalopathy. *J Gen Virol* **86**, 839–848.
- Moudjou, M., Frobert, Y., Grassi, J. & La Bonnardière, C. (2001).** Cellular prion protein status in sheep: tissue-specific biochemical signatures. *J Gen Virol* **82**, 2017–2024.
- Moum, T., Olsaker, I., Hopp, P., Moldal, T., Valheim, M., Moum, T. & Benestad, S. L. (2005).** Polymorphisms at codons 141 and 154 in the ovine prion protein gene are associated with scrapie Nor98 cases. *J Gen Virol* **86**, 231–235.
- Onnasch, H., Gunn, H. M., Bradshaw, B. J., Benestad, S. L. & Bassett, H. F. (2004).** Two Irish cases of scrapie resembling Nor98. *Vet Rec* **155**, 636–637.
- Orge, L., Galo, A., Machado, C., Lima, C., Ochoa, C., Silva, J., Ramos, M. & Simas, J. P. (2004).** Identification of putative atypical scrapie in sheep in Portugal. *J Gen Virol* **85**, 3487–3491.
- O'Rourke, K. I., Baszler, T. V., Miller, J. M., Spraker, T. R., Sadler-Riggelman, I. & Knowles, D. P. (1998).** Monoclonal antibody F89/160.1.5 defines a conserved epitope on the ruminant prion protein. *J Clin Microbiol* **36**, 1750–1755.
- O'Rourke, K. I., Baszler, T. V., Besser, T. E. & 9 other authors (2000).** Preclinical diagnosis of scrapie by immunohistochemistry of third eyelid lymphoid tissue. *J Clin Microbiol* **38**, 3254–3259.
- Salmona, M., Morbin, M., Massignan, T. & 14 other authors (2003).** Structural properties of Gerstmann-Sträussler-Scheinker disease amyloid protein. *J Biol Chem* **278**, 48146–48153.

Spraker, T. R., O'Rourke, K. I., Balachandran, A., Zink, R. R., Cummings, B. A., Miller, M. W. & Powers, B. E. (2002). Validation of monoclonal antibody F99/97.6.1 for immunohistochemical staining of brain and tonsil in mule deer (*Odocoileus hemionus*) with chronic wasting disease. *J Vet Diagn Invest* **14**, 3–7.

Stack, M. J., Chaplin, M. J. & Clark, J. (2002). Differentiation of prion protein glycoforms from naturally occurring sheep scrapie, sheep-passaged scrapie strains (CH1641 and SSBP1), bovine spongiform encephalopathy (BSE) cases and Romney and Cheviot breed sheep experimentally inoculated with BSE using two monoclonal antibodies. *Acta Neuropathol* **104**, 279–286.

Tagliavini, F., Lievens, P. M.-J., Tranchant, C. & 12 other authors (2001). A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117V. *J Biol Chem* **276**, 6009–6015.

Thuring, C. M. A., Erkens, J. H. F., Jacobs, J. G. & 8 other authors (2004). Discrimination between scrapie and bovine spongiform encephalopathy in sheep by molecular size, immunoreactivity, and glycoprofile of prion protein. *J Clin Microbiol* **42**, 972–980.

Wadsworth, J. D. F., Joiner, S., Hill, A. F., Campbell, T. A., Desbruslais, M., Luthert, P. J. & Collinge, J. (2001). Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. *Lancet* **358**, 171–180.

White, A. R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D., Collinge, J. & Hawke, S. (2003). Monoclonal antibodies inhibit prion replication and delay the development of prion disease. *Nature* **422**, 80–83.

Yull, H. M., Ritchie, D. L., Langeveld, J. P. M., van Zijderveld, F. G., Bruce, M. E., Ironside, J. W. & Head, M. W. (2006). Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. *Am J Pathol* **168**, 151–157.